PT-141 + Kisspeptin-10 Sexual Health Research Stack | QSC
QSC · RESEARCH CATALOG
PT-141 + Kisspeptin-10 Sexual Health Research Stack MC4R Central Arousal + HPG Axis Activation · Two-Pathway Sexual Health Research · ≥99% HPLC · Janoshik COA
PT-141 (Bremelanotide, FDA-approved MC4R agonist) and Kisspeptin-10 (KISS1R/GPR54 HPG axis activator) address sexual health research through entirely different mechanisms. PT-141 works centrally — MC4R activation drives hypothalamic dopamine signaling for arousal/desire. Kisspeptin-10 works on the gonadal axis — KISS1R stimulation triggers GnRH → LH/FSH → testosterone/estrogen cascade. Combined, they represent the most comprehensive dual-pathway sexual health research protocol available.
Master regulator of puberty onset and reproductive axis — upstream of the entire HPG axis
Studied in hypogonadism, infertility, and HPG axis restoration after suppression
Active clinical research: IVF protocols, testosterone restoration, reproductive medicine
Frequently Asked Questions
What is the PT-141 + Kisspeptin research combination?
PT-141 (MC4R central arousal) + Kisspeptin-10 (KISS1R HPG axis gonadotropin release) covers both the central desire/arousal circuit and the gonadal steroidogenesis axis. Non-overlapping mechanisms. QSC stocks both at ≥99% HPLC with Janoshik COA. Research use only.
Is PT-141 FDA-approved?
Yes — PT-141 (Bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women (Palatin Technologies/AMAG, 2019). QSC stocks the research-grade compound at ≥99% HPLC with Janoshik COA. Research use only.
Does QSC stock both PT-141 and Kisspeptin-10?
Yes — QSC stocks both PT-141 (Bremelanotide) and Kisspeptin-10 at ≥99% HPLC with Janoshik independent COA verifiable at verify.janoshik.com. Research use only.
